Drug Profile
JNJ 5806
Alternative Names: AL-794; Influenza virus polymerase PA subunit inhibitor - Alios BioPharma; Influenza virus RNA polymerase inhibitor - Alios BioPharma; JNJ-5806; JNJ-64155806Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Alios BioPharma
- Class Antivirals
- Mechanism of Action RNA replicase inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 May 2020 No recent reports of development identified for phase-I development in Influenza-virus-infections(In volunteers) in USA (PO, Tablet)
- 28 Jul 2019 No recent reports of development identified for phase-I development in Influenza-virus-infections(In volunteers) in United Kingdom (PO, Tablet)
- 28 Sep 2018 No recent reports of development identified for phase-I development in Influenza-virus-infections(In volunteers) in United Kingdom (PO, Suspension)